Skip to main content
SpringerLink
Log in

Obesity-Associated Hypertension: the Upcoming Phenotype in African-American Women

  • Hypertension and Obesity (E Reisin, Section Editor)
  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The present obesity epidemic particularly affects African-American women. Whether the obesity epidemic will alter the hypertension phenotype in African-American women is entertained.

Recent Findings

The prevalence of morbid obesity is steadily increasing in African-American women, who are prone to developing hypertension (HTN) even in the absence of obesity. The obesity-associated hypertension phenotype is characterized by marked sympathetic nervous system activation and resistance/refractoriness to antihypertensive therapy. Weight loss achieved through lifestyle interventions and pharmacotherapy has a modest and rarely sustained antihypertensive effect. In contrast, bariatric surgery has a sustained antihypertensive effect, as evidenced by normalization of hypertension or lessening of antihypertensive therapy.

Summary

The prevalence of HTN and its obesity-associated phenotype is likely to increase in African-American women over the next decades. Obese African-American women may be increasingly referred for bariatric surgery when hypertension remains uncontrolled despite lifestyle interventions and pharmacological therapy for weight loss and blood pressure (BP) control.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9945):766–81. doi:10.1016/S0140-6736(14)60460-8.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Dutton GR, Kim Y, Jacobs DR, Li X, Loria CM, Reis JP, et al. 25-year weight gain in a racially balanced sample of U.S. adults: the CARDIA study. Obesity (Silver Spring). 2016;24(9):1962–8. doi:10.1002/oby.21573.

    Article  Google Scholar 

  3. Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in obesity among adults in the United States, 2005 to 2014. JAMA. 2016;315(21):2284–91. doi:10.1001/jama.2016.6458.

    Article  CAS  PubMed  Google Scholar 

  4. Wang Y, Beydoun MA, Liang L, Caballero B, Kumanyika SK. Will all Americans become overweight or obese? Estimating the progression and cost of the US obesity epidemic. Obesity (Silver Spring). 2008;16(10):2323–30. doi:10.1038/oby.2008.351.

    Article  Google Scholar 

  5. Guo F, He D, Zhang W, Walton RG. Trends in prevalence, awareness, management, and control of hypertension among United States adults, 1999 to 2010. J Am Coll Cardiol. 2012;60(7):599–606. doi:10.1016/j.jacc.2012.04.026.

    Article  PubMed  Google Scholar 

  6. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6–e245. doi:10.1161/CIR.0b013e31828124ad.

    Article  PubMed  Google Scholar 

  7. Bramlage P, Pittrow D, Wittchen HU, Kirch W, Boehler S, Lehnert H, et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens. 2004;17(10):904–10. doi:10.1016/j.amjhyper.2004.05.017.

    Article  PubMed  Google Scholar 

  8. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51(6):1403–19. doi:10.1161/HYPERTENSIONAHA.108.189141.

    Article  CAS  PubMed  Google Scholar 

  9. Yang L, Colditz GA. Prevalence of overweight and obesity in the United States, 2007-2012. JAMA Intern Med. 2015;175(8):1412–3. doi:10.1001/jamainternmed.2015.2405.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA. 1994;272(3):205–11.

    Article  CAS  PubMed  Google Scholar 

  11. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002;288(14):1723–7.

    Article  PubMed  Google Scholar 

  12. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006;295(13):1549–55. doi:10.1001/jama.295.13.1549.

    Article  CAS  PubMed  Google Scholar 

  13. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014;311(8):806–14. doi:10.1001/jama.2014.732.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Lackland DT. Racial differences in hypertension: implications for high blood pressure management. Am J Med Sci. 2014;348(2):135–8. doi:10.1097/MAJ.0000000000000308.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Gillum RF. Overweight and obesity in black women: a review of published data from the National Center for Health Statistics. J Natl Med Assoc. 1987;79(8):865–71.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Lackland DT, Orchard TJ, Keil JE, Saunders DE, Wheeler FC, Adams-Campbell LL, et al. Are race differences in the prevalence of hypertension explained by body mass and fat distribution? A survey in a biracial population. Int J Epidemiol. 1992;21(2):236–45.

    Article  CAS  PubMed  Google Scholar 

  17. Cossrow N, Falkner B. Race/ethnic issues in obesity and obesity-related comorbidities. J Clin Endocrinol Metab. 2004;89(6):2590–4. doi:10.1210/jc.2004-0339.

    Article  CAS  PubMed  Google Scholar 

  18. Bleich SN, Thorpe RJ, Sharif-Harris H, Fesahazion R, Laveist TA. Social context explains race disparities in obesity among women. J Epidemiol Community Health. 2010;64(5):465–9. doi:10.1136/jech.2009.096297.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Barrington DS, Baquero MC, Borrell LN, Crawford ND. Racial/ethnic disparities in obesity among US-born and foreign-born adults by sex and education. Obesity (Silver Spring). 2010;18(2):422–4. doi:10.1038/oby.2009.212.

    Article  Google Scholar 

  20. Jackson CL, Szklo M, Yeh HC, Wang NY, Dray-Spira R, Thorpe R, et al. Black-white disparities in overweight and obesity trends by educational attainment in the United States, 1997-2008. J Obes. 2013;2013:140743. doi:10.1155/2013/140743.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Harris MM, Stevens J, Thomas N, Schreiner P, Folsom AR. Associations of fat distribution and obesity with hypertension in a bi-ethnic population: the ARIC study. Atherosclerosis Risk in Communities Study. Obes Res. 2000;8(7):516–24. doi:10.1038/oby.2000.64.

    Article  CAS  PubMed  Google Scholar 

  22. Tchernof A, Després JP. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013;93(1):359–404. doi:10.1152/physrev.00033.2011.

    Article  CAS  PubMed  Google Scholar 

  23. Neeland IJ, Gupta S, Ayers CR, Turer AT, Rame JE, Das SR, et al. Relation of regional fat distribution to left ventricular structure and function. Circ Cardiovasc Imaging. 2013;6(5):800–7. doi:10.1161/CIRCIMAGING.113.000532.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Després JP, Couillard C, Gagnon J, Bergeron J, Leon AS, Rao DC, et al. Race, visceral adipose tissue, plasma lipids, and lipoprotein lipase activity in men and women: the Health, Risk Factors, Exercise Training, and Genetics (HERITAGE) family study. Arterioscler Thromb Vasc Biol. 2000;20(8):1932–8.

    Article  PubMed  Google Scholar 

  25. DeMarco VG, Aroor AR, Sowers JR. The pathophysiology of hypertension in patients with obesity. Nat Rev Endocrinol. 2014;10(6):364–76. doi:10.1038/nrendo.2014.44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015;116(6):991–1006. doi:10.1161/CIRCRESAHA.116.305697.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Rossier BC. 1996 Homer Smith Award Lecture. Cum grano salis: the epithelial sodium channel and the control of blood pressure. J Am Soc Nephrol. 1997;8(6):980–92.

    CAS  PubMed  Google Scholar 

  28. Yang J, Villar VA, Armando I, Jose PA, Zeng C. G protein-coupled receptor kinases: crucial regulators of blood pressure. J Am Heart Assoc. 2016;5(7) doi:10.1161/JAHA.116.003519.

  29. Rossier BC, Schild L. Epithelial sodium channel: Mendelian versus essential hypertension. Hypertension. 2008;52(4):595–600. doi:10.1161/HYPERTENSIONAHA.107.097147.

    Article  CAS  PubMed  Google Scholar 

  30. Rotin D, Staub O. Nedd4-2 and the regulation of epithelial sodium transport. Front Physiol. 2012;3:212. doi:10.3389/fphys.2012.00212.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Bubien JK. Epithelial Na+ channel (ENaC), hormones, and hypertension. J Biol Chem. 2010;285(31):23527–31. doi:10.1074/jbc.R109.025049.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Nizar JM, Dong W, McClellan RB, Labarca M, Zhou Y, Wong J, et al. Na+-sensitive elevation in blood pressure is ENaC independent in diet-induced obesity and insulin resistance. Am J Physiol Renal Physiol. 2016;310(9):F812–20. doi:10.1152/ajprenal.00265.2015.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Rayner BL, Spence JD. Hypertension in blacks: insights from Africa. J Hypertens. 2017;35(2):234–9. doi:10.1097/HJH.0000000000001171.

    Article  CAS  PubMed  Google Scholar 

  34. Hall JE, da Silva AA, do Carmo JM, Dubinion J, Hamza S, Munusamy S, et al. Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins. J Biol Chem. 2010;285(23):17271–6. doi:10.1074/jbc.R110.113175.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Sutton AK, Myers MG, Olson DP. The role of PVH circuits in leptin action and energy balance. Annu Rev Physiol. 2016;78:207–21. doi:10.1146/annurev-physiol-021115-105347.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. da Silva AA, do Carmo JM, Hall JE. Role of leptin and central nervous system melanocortins in obesity hypertension. Curr Opin Nephrol Hypertens. 2013;22(2):135–40. doi:10.1097/MNH.0b013e32835d0c05.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  37. Harlan SM, Rahmouni K. Neuroanatomical determinants of the sympathetic nerve responses evoked by leptin. Clin Auton Res. 2013;23(1):1–7. doi:10.1007/s10286-012-0168-4.

    Article  PubMed  Google Scholar 

  38. do Carmo JM, da Silva AA, Wang Z, Fang T, Aberdein N, de Lara Rodriguez CE, et al. Obesity-induced hypertension: brain signaling pathways. Curr Hypertens Rep. 2016;18(7):58. doi:10.1007/s11906-016-0658-1.

    Article  PubMed  CAS  Google Scholar 

  39. Shimizu H, Inoue K, Mori M. The leptin-dependent and -independent melanocortin signaling system: regulation of feeding and energy expenditure. J Endocrinol. 2007;193(1):1–9. doi:10.1677/JOE-06-0144.

    Article  CAS  PubMed  Google Scholar 

  40. Rahmouni K. Cardiovascular regulation by the arcuate nucleus of the hypothalamus: neurocircuitry and signaling systems. Hypertension. 2016;67(6):1064–71. doi:10.1161/HYPERTENSIONAHA.115.06425.

    Article  CAS  PubMed  Google Scholar 

  41. Mark AL. Selective leptin resistance revisited. Am J Physiol Regul Integr Comp Physiol. 2013;305(6):R566–81. doi:10.1152/ajpregu.00180.2013.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Harlan SM, Rahmouni K. PI3K signaling: a key pathway in the control of sympathetic traffic and arterial pressure by leptin. Mol Metab. 2013;2(2):69–73. doi:10.1016/j.molmet.2013.03.004.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Esler M, Straznicky N, Eikelis N, Masuo K, Lambert G, Lambert E. Mechanisms of sympathetic activation in obesity-related hypertension. Hypertension. 2006;48(5):787–96. doi:10.1161/01.HYP.0000242642.42177.49.

    Article  CAS  PubMed  Google Scholar 

  44. Grassi G, Mark A, Esler M. The sympathetic nervous system alterations in human hypertension. Circ Res. 2015;116(6):976–90. doi:10.1161/CIRCRESAHA.116.303604.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Machleidt F, Simon P, Krapalis AF, Hallschmid M, Lehnert H, Sayk F. Experimental hyperleptinemia acutely increases vasoconstrictory sympathetic nerve activity in healthy humans. J Clin Endocrinol Metab. 2013;98(3):E491–6. doi:10.1210/jc.2012-3009.

    Article  CAS  PubMed  Google Scholar 

  46. Momin AU, Melikian N, Shah AM, Grieve DJ, Wheatcroft SB, John L, et al. Leptin is an endothelial-independent vasodilator in humans with coronary artery disease: evidence for tissue specificity of leptin resistance. Eur Heart J. 2006;27(19):2294–9. doi:10.1093/eurheartj/ehi831.

    Article  CAS  PubMed  Google Scholar 

  47. Shankar A, Xiao J. Positive relationship between plasma leptin level and hypertension. Hypertension. 2010;56(4):623–8. doi:10.1161/HYPERTENSIONAHA.109.148213.

    Article  CAS  PubMed  Google Scholar 

  48. Apovian CM. The obesity epidemic—understanding the disease and the treatment. N Engl J Med. 2016;374(2):177–9. doi:10.1056/NEJMe1514957.

    Article  PubMed  Google Scholar 

  49. Huby AC, Antonova G, Groenendyk J, Gomez-Sanchez CE, Bollag WB, Filosa JA, et al. Adipocyte-derived hormone leptin is a direct regulator of aldosterone secretion, which promotes endothelial dysfunction and cardiac fibrosis. Circulation. 2015;132(22):2134–45. doi:10.1161/CIRCULATIONAHA.115.018226.

    Article  CAS  PubMed  Google Scholar 

  50. Xie D, Bollag WB. Obesity, hypertension and aldosterone: is leptin the link? J Endocrinol. 2016;230(1):F7–F11. doi:10.1530/JOE-16-0160.

    Article  CAS  PubMed  Google Scholar 

  51. Galmiche G, Pizard A, Gueret A, El Moghrabi S, Ouvrard-Pascaud A, Berger S, et al. Smooth muscle cell mineralocorticoid receptors are mandatory for aldosterone-salt to induce vascular stiffness. Hypertension. 2014;63(3):520–6. doi:10.1161/HYPERTENSIONAHA.113.01967.

    Article  CAS  PubMed  Google Scholar 

  52. Briet M. Mineralocorticoid receptor, the main player in aldosterone-induced large artery stiffness. Hypertension. 2014;63(3):442–3. doi:10.1161/HYPERTENSIONAHA.113.02581.

    Article  CAS  PubMed  Google Scholar 

  53. Fuchs FD. Why do black Americans have higher prevalence of hypertension?: an enigma still unsolved. Hypertension. 2011;57(3):379–80. doi:10.1161/HYPERTENSIONAHA.110.163196.

    Article  CAS  PubMed  Google Scholar 

  54. Gupta DK, Claggett B, Wells Q, Cheng S, Li M, Maruthur N, et al. Racial differences in circulating natriuretic peptide levels: the atherosclerosis risk in communities study. J Am Heart Assoc. 2015;4(5) doi:10.1161/JAHA.115.001831.

  55. Nagase M, Yoshida S, Shibata S, Nagase T, Gotoda T, Ando K, et al. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol. 2006;17(12):3438–46. doi:10.1681/ASN.2006080944.

    Article  CAS  PubMed  Google Scholar 

  56. Briones AM, Nguyen Dinh Cat A, Callera GE, Yogi A, Burger D, He Y, et al. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension. 2012;59(5):1069–78. doi:10.1161/HYPERTENSIONAHA.111.190223.

    Article  CAS  PubMed  Google Scholar 

  57. Nguyen Dinh Cat A, Briones AM, Callera GE, Yogi A, He Y, Montezano AC, et al. Adipocyte-derived factors regulate vascular smooth muscle cells through mineralocorticoid and glucocorticoid receptors. Hypertension. 2011;58(3):479–88. doi:10.1161/HYPERTENSIONAHA.110.168872.

    Article  CAS  PubMed  Google Scholar 

  58. Dudenbostel T, Ghazi L, Liu M, Li P, Oparil S, Calhoun DA. Body mass index predicts 24-hour urinary aldosterone levels in patients with resistant hypertension. Hypertension. 2016;68(4):995–1003. doi:10.1161/HYPERTENSIONAHA.116.07806.

    Article  CAS  PubMed  Google Scholar 

  59. Cassis LA, Police SB, Yiannikouris F, Thatcher SE. Local adipose tissue renin-angiotensin system. Curr Hypertens Rep. 2008;10(2):93–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Aroor AR, DeMarco VG. Oxidative stress and obesity: the chicken or the egg? Diabetes. 2014;63(7):2216–8. doi:10.2337/db14-0424.

    Article  PubMed  Google Scholar 

  61. Pratt JH, Jones JJ, Miller JZ, Wagner MA, Fineberg NS. Racial differences in aldosterone excretion and plasma aldosterone concentrations in children. N Engl J Med. 1989;321(17):1152–7. doi:10.1056/NEJM198910263211703.

    Article  CAS  PubMed  Google Scholar 

  62. Flack JM, Sica DA, Bakris G, Brown AL, Ferdinand KC, Grimm RH, et al. Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension. 2010;56(5):780–800. doi:10.1161/HYPERTENSIONAHA.110.152892.

    Article  CAS  PubMed  Google Scholar 

  63. Wright JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288(19):2421–31.

    Article  CAS  PubMed  Google Scholar 

  64. Weir MR, Gray JM, Paster R, Saunders E. Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. The Trandolapril Multicenter Study Group Hypertension. 1995;26(1):124–30.

    CAS  PubMed  Google Scholar 

  65. Norris KC, Tareen N, Martins D, Vaziri ND. Implications of ethnicity for the treatment of hypertensive kidney disease, with an emphasis on African Americans. Nat Clin Pract Nephrol. 2008;4(10):538–49. doi:10.1038/ncpneph0909.

    Article  PubMed  Google Scholar 

  66. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285(21):2719–28.

    Article  CAS  PubMed  Google Scholar 

  67. Williams SF, Nicholas SB, Vaziri ND, Norris KC. African Americans, hypertension and the renin angiotensin system. World J Cardiol. 2014;6(9):878–89. doi:10.4330/wjc.v6.i9.878.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A, et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. J Am Coll Cardiol. 2008;52(8):686–717. doi:10.1016/j.jacc.2008.05.002.

    Article  PubMed  Google Scholar 

  69. Konecny T, Kara T, Somers VK. Obstructive sleep apnea and hypertension: an update. Hypertension. 2014;63(2):203–9. doi:10.1161/HYPERTENSIONAHA.113.00613.

    Article  CAS  PubMed  Google Scholar 

  70. Abboud F, Kumar R. Obstructive sleep apnea and insight into mechanisms of sympathetic overactivity. J Clin Invest. 2014;124(4):1454–7. doi:10.1172/JCI70420.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Cunningham JT, Knight WD, Mifflin SW, Nestler EJ. An essential role for DeltaFosB in the median preoptic nucleus in the sustained hypertensive effects of chronic intermittent hypoxia. Hypertension. 2012;60(1):179–87. doi:10.1161/HYPERTENSIONAHA.112.193789.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Shell B, Faulk K, Cunningham JT. Neural control of blood pressure in chronic intermittent hypoxia. Curr Hypertens Rep. 2016;18(3):19. doi:10.1007/s11906-016-0627-8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  73. McEvoy RD, Antic NA, Heeley E, Luo Y, Ou Q, Zhang X, et al. CPAP for prevention of cardiovascular events in obstructive sleep apnea. N Engl J Med. 2016;375(10):919–31. doi:10.1056/NEJMoa1606599.

    Article  PubMed  Google Scholar 

  74. Iftikhar IH, Valentine CW, Bittencourt LR, Cohen DL, Fedson AC, Gíslason T, et al. Effects of continuous positive airway pressure on blood pressure in patients with resistant hypertension and obstructive sleep apnea: a meta-analysis. J Hypertens. 2014;32(12):2341–50. doi:10.1097/HJH.0000000000000372. discussion 50

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Landsberg L, Aronne LJ, Beilin LJ, Burke V, Igel LI, Lloyd-Jones D, et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment—a position paper of the Obesity Society and the American Society of Hypertension. Obesity (Silver Spring). 2013;21(1):8–24. doi:10.1002/oby.20181.

    Article  Google Scholar 

  76. Bloch MJ, Viera AJ. Should patients with obesity and hypertension be treated differently from those who are not obese? Curr Hypertens Rep. 2014;16(3):418. doi:10.1007/s11906-014-0418-z.

    Article  PubMed  CAS  Google Scholar 

  77. Wassertheil-Smoller S, Fann C, Allman RM, Black HR, Camel GH, Davis B, et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Arch Intern Med. 2000;160(4):494–500.

    Article  CAS  PubMed  Google Scholar 

  78. Weber MA, Jamerson K, Bakris GL, Weir MR, Zappe D, Zhang Y, et al. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet. 2013;381(9866):537–45. doi:10.1016/S0140-6736(12)61343-9.

    Article  PubMed  Google Scholar 

  79. Trial AOaCftACRGTAaL-LTtPHA. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–97.

    Article  Google Scholar 

  80. Zanella MT, Kohlmann O, Ribeiro AB. Treatment of obesity hypertension and diabetes syndrome. Hypertension. 2001;38(3 Pt 2):705–8.

    Article  CAS  PubMed  Google Scholar 

  81. Masuo K, Mikami H, Ogihara T, Tuck ML. Weight reduction and pharmacologic treatment in obese hypertensives. Am J Hypertens. 2001;14(6 Pt 1):530–8.

    Article  CAS  PubMed  Google Scholar 

  82. Sharma AM, Pischon T, Engeli S, Scholze J. Choice of drug treatment for obesity-related hypertension: where is the evidence? J Hypertens. 2001;19(4):667–74.

    Article  CAS  PubMed  Google Scholar 

  83. Wofford MR, Smith G, Minor DS. The treatment of hypertension in obese patients. Curr Hypertens Rep. 2008;10(2):143–50.

    Article  CAS  PubMed  Google Scholar 

  84. Abuissa H, Jones PG, Marso SP, O'Keefe JH. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol. 2005;46(5):821–6. doi:10.1016/j.jacc.2005.05.051.

    Article  CAS  PubMed  Google Scholar 

  85. Kidambi S, Kotchen TA. Treatment of hypertension in obese patients. Am J Cardiovasc Drugs. 2013;13(3):163–75. doi:10.1007/s40256-013-0008-5.

    Article  CAS  PubMed  Google Scholar 

  86. de Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension. 2010;55(1):147–52. doi:10.1161/HYPERTENSIONAHA.109.140988.

    Article  PubMed  CAS  Google Scholar 

  87. Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059–68. doi:10.1016/S0140-6736(15)00257-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Mertens IL, Van Gaal LF. Overweight, obesity, and blood pressure: the effects of modest weight reduction. Obes Res. 2000;8(3):270–8. doi:10.1038/oby.2000.32.

    Article  CAS  PubMed  Google Scholar 

  89. Middlemiss JE, McEniery CM. Feeling the pressure: (patho) physiological mechanisms of weight gain and weight loss in humans. Hypertens Res. 2017;40(3):226–36. doi:10.1038/hr.2016.142.

    Article  PubMed  Google Scholar 

  90. Appel LJ, Brands MW, Daniels SR, Karanja N, Elmer PJ, Sacks FM. Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension. 2006;47(2):296–308. doi:10.1161/01.hyp.0000202568.01167.b6.

    Article  CAS  PubMed  Google Scholar 

  91. Whelton PK, Appel LJ, Espeland MA, Applegate WB, Ettinger WH, Kostis JB, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA. 1998;279(11):839–46.

    Article  CAS  PubMed  Google Scholar 

  92. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2003;42(5):878–84. doi:10.1161/01.HYP.0000094221.86888.AE.

    Article  CAS  PubMed  Google Scholar 

  93. Engeli S, Böhnke J, Gorzelniak K, Janke J, Schling P, Bader M, et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension. 2005;45(3):356–62. doi:10.1161/01.HYP.0000154361.47683.d3.

    Article  CAS  PubMed  Google Scholar 

  94. Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med. 1981;304(16):930–3. doi:10.1056/NEJM198104163041602.

    Article  CAS  PubMed  Google Scholar 

  95. Mark AL. Dietary therapy for obesity: an emperor with no clothes. Hypertension. 2008;51(6):1426–34. doi:10.1161/HYPERTENSIONAHA.106.085944. discussion 34

    Article  CAS  PubMed  Google Scholar 

  96. Fitzgibbon ML, Tussing-Humphreys LM, Porter JS, Martin IK, Odoms-Young A, Sharp LK. Weight loss and African-American women: a systematic review of the behavioural weight loss intervention literature. Obes Rev. 2012;13(3):193–213. doi:10.1111/j.1467-789X.2011.00945.x.

    Article  CAS  PubMed  Google Scholar 

  97. Kumanyika SK, Whitt-Glover MC, Haire-Joshu D. What works for obesity prevention and treatment in black Americans? Research directions. Obes Rev. 2014;15(Suppl 4):204–12. doi:10.1111/obr.12213.

    Article  PubMed  Google Scholar 

  98. Appel LJ, Champagne CM, Harsha DW, Cooper LS, Obarzanek E, Elmer PJ, et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA. 2003;289(16):2083–93. doi:10.1001/jama.289.16.2083.

    PubMed  Google Scholar 

  99. Wingo BC, Carson TL, Ard J. Differences in weight loss and health outcomes among African Americans and whites in multicentre trials. Obes Rev. 2014;15(Suppl 4):46–61. doi:10.1111/obr.12212.

    Article  PubMed  Google Scholar 

  100. Agyemang P, Powell-Wiley TM. Obesity and Black women: special considerations related to genesis and therapeutic approaches. Curr Cardiovasc Risk Rep. 2013;7(5):378–86. doi:10.1007/s12170-013-0328-7.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian A, Brethauer SA, et al. Bariatric surgery versus intensive medical therapy for diabetes—5-year outcomes. N Engl J Med. 2017;376(7):641–51. doi:10.1056/NEJMoa1600869.

    Article  PubMed  Google Scholar 

  102. Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. N Engl J Med. 2017;376(3):254–66. doi:10.1056/NEJMra1514009.

    Article  PubMed  Google Scholar 

  103. Dombrowski SU, Knittle K, Avenell A, Araújo-Soares V, Sniehotta FF. Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials. BMJ. 2014;348:g2646.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Siebenhofer A, Jeitler K, Horvath K, Berghold A, Posch N, Meschik J, et al. Long-term effects of weight-reducing drugs in people with hypertension. Cochrane Database Syst Rev. 2016;3:CD007654. doi:10.1002/14651858.CD007654.pub4.

    PubMed  Google Scholar 

  105. Patel D. Pharmacotherapy for the management of obesity. Metabolism. 2015;64(11):1376–85. doi:10.1016/j.metabol.2015.08.001.

    Article  CAS  PubMed  Google Scholar 

  106. Bakris G, Calhoun D, Egan B, Hellmann C, Dolker M, Kingma I, et al. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens. 2002;20(11):2257–67.

    Article  CAS  PubMed  Google Scholar 

  107. Kelley DE, Bray GA, Pi-Sunyer FX, Klein S, Hill J, Miles J, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2002;25(6):1033–41.

    Article  CAS  PubMed  Google Scholar 

  108. Sharma AM, Golay A. Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension. J Hypertens. 2002;20(9):1873–8.

    Article  CAS  PubMed  Google Scholar 

  109. Vorsanger MH, Subramanyam P, Weintraub HS, Lamm SH, Underberg JA, Gianos E, et al. Cardiovascular effects of the new weight loss agents. J Am Coll Cardiol. 2016;68(8):849–59. doi:10.1016/j.jacc.2016.06.007.

    Article  CAS  PubMed  Google Scholar 

  110. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341–52. doi:10.1016/S0140-6736(11)60205-5.

    Article  CAS  PubMed  Google Scholar 

  111. Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363(3):245–56. doi:10.1056/NEJMoa0909809.

    Article  CAS  PubMed  Google Scholar 

  112. Wolfe BM, Kvach E, Eckel RH. Treatment of obesity: weight loss and bariatric surgery. Circ Res. 2016;118(11):1844–55. doi:10.1161/CIRCRESAHA.116.307591.

    Article  CAS  PubMed  Google Scholar 

  113. Adams TD, Davidson LE, Litwin SE, Kolotkin RL, LaMonte MJ, Pendleton RC, et al. Health benefits of gastric bypass surgery after 6 years. JAMA. 2012;308(11):1122–31. doi:10.1001/2012.jama.11164.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Tritsch AM, Bland CM, Hatzigeorgiou C, Sweeney LB, Phillips M. A retrospective review of the medical management of hypertension and diabetes mellitus following sleeve gastrectomy. Obes Surg. 2015;25(4):642–7. doi:10.1007/s11695-014-1375-y.

    Article  PubMed  Google Scholar 

  115. Ricci C, Gaeta M, Rausa E, Asti E, Bandera F, Bonavina L. Long-term effects of bariatric surgery on type II diabetes, hypertension and hyperlipidemia: a meta-analysis and meta-regression study with 5-year follow-up. Obes Surg. 2015;25(3):397–405. doi:10.1007/s11695-014-1442-4.

    Article  PubMed  Google Scholar 

  116. Hatoum IJ, Blackstone R, Hunter TD, Francis DM, Steinbuch M, Harris JL, et al. Clinical factors associated with remission of obesity-related comorbidities after bariatric surgery. JAMA Surg. 2016;151(2):130–7. doi:10.1001/jamasurg.2015.3231.

    Article  PubMed  Google Scholar 

  117. Adams ST, Salhab M, Hussain ZI, Miller GV, Leveson SH. Obesity-related hypertension and its remission following gastric bypass surgery—a review of the mechanisms and predictive factors. Blood Press. 2013;22(3):131–7. doi:10.3109/08037051.2012.749570.

    Article  PubMed  Google Scholar 

  118. Frühbeck G. Bariatric and metabolic surgery: a shift in eligibility and success criteria. Nat Rev Endocrinol. 2015;11(8):465–77. doi:10.1038/nrendo.2015.84.

    Article  PubMed  Google Scholar 

  119. Ionut V, Burch M, Youdim A, Bergman RN. Gastrointestinal hormones and bariatric surgery-induced weight loss. Obesity (Silver Spring). 2013;21(6):1093–103. doi:10.1002/oby.20364.

    Article  CAS  Google Scholar 

  120. Almgren T, Persson B, Wilhelmsen L, Rosengren A, Andersson OK. Stroke and coronary heart disease in treated hypertension—a prospective cohort study over three decades. J Intern Med. 2005;257(6):496–502. doi:10.1111/j.1365-2796.2005.01497.x.

    Article  CAS  PubMed  Google Scholar 

  121. Andersson OK, Almgren T, Persson B, Samuelsson O, Hedner T, Wilhelmsen L. Survival in treated hypertension: follow up study after two decades. BMJ. 1998;317(7152):167–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  122. Blacher J, Evans A, Arveiler D, Amouyel P, Ferrières J, Bingham A, et al. Residual cardiovascular risk in treated hypertension and hyperlipidaemia: the PRIME Study. J Hum Hypertens. 2010;24(1):19–26. doi:10.1038/jhh.2009.34.

    Article  CAS  PubMed  Google Scholar 

  123. Howard G, Safford MM, Moy CS, Howard VJ, Kleindorfer DO, Unverzagt FW, et al. Racial differences in the incidence of cardiovascular risk factors in older black and white adults. J Am Geriatr Soc. 2017;65(1):83–90. doi:10.1111/jgs.14472.

    Article  PubMed  Google Scholar 

  124. Wolk R, Bertolet M, Singh P, Brooks MM, Pratley RE, Frye RL, et al. Prognostic value of adipokines in predicting cardiovascular outcome: explaining the obesity paradox. Mayo Clin Proc. 2016;91(7):858–66. doi:10.1016/j.mayocp.2016.03.020.

    Article  CAS  PubMed  Google Scholar 

  125. Fuster JJ, Ouchi N, Gokce N, Walsh K. Obesity-induced changes in adipose tissue microenvironment and their impact on cardiovascular disease. Circ Res. 2016;118(11):1786–807. doi:10.1161/CIRCRESAHA.115.306885.

    Article  CAS  PubMed  Google Scholar 

  126. Ye J. Emerging role of adipose tissue hypoxia in obesity and insulin resistance. Int J Obes. 2009;33(1):54–66. doi:10.1038/ijo.2008.229.

    Article  CAS  Google Scholar 

  127. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112(12):1796–808. doi:10.1172/JCI19246.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  128. Schmiegelow MD, Hedlin H, Mackey RH, Martin LW, Vitolins MZ, Stefanick ML, et al. Race and ethnicity, obesity, metabolic health, and risk of cardiovascular disease in postmenopausal women. J Am Heart Assoc. 2015;4(5) doi:10.1161/JAHA.114.001695.

  129. Varbo A, Benn M, Smith GD, Timpson NJ, Tybjaerg-Hansen A, Nordestgaard BG. Remnant cholesterol, low-density lipoprotein cholesterol, and blood pressure as mediators from obesity to ischemic heart disease. Circ Res. 2015;116(4):665–73. doi:10.1161/CIRCRESAHA.116.304846.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, Tulane University School of Medicine, 1430 Tulane Avenue, SL-48, New Orleans, LA, 70112, USA

    Rohan Samson, Andrea Qi, Abhishek Jaiswal & Thierry H. Le Jemtel

  2. Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham (UAB), Birmingham, AL, USA

    Suzanne Oparil

Authors
  1. Rohan Samson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrea Qi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Abhishek Jaiswal
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Thierry H. Le Jemtel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Suzanne Oparil
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thierry H. Le Jemtel.

Ethics declarations

Conflict of Interest

The authors declare no conflicts of interest relevant to this manuscript.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Hypertension and Obesity

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Samson, R., Qi, A., Jaiswal, A. et al. Obesity-Associated Hypertension: the Upcoming Phenotype in African-American Women. Curr Hypertens Rep 19, 41 (2017). https://doi.org/10.1007/s11906-017-0738-x

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11906-017-0738-x

Keywords

Search

Navigation